CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ — Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American…